Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01283022 · ClinicalTrials.gov registry record · Phase 2

Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

A Phase 2 study of Cervical Ripening and Induction of Labor, sponsored by Ferring Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target
1
Study location

NCT01283022 is a Phase 2 study of Cervical Ripening and Induction of Labor that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 24 participants, below the 468-participant average among 8 other Cervical Ripening trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01283022, a Phase 2 study of Cervical Ripening and Induction of Labor, has completed, sponsored by Ferring Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.

Interventions

  • DRUG MVI 200

Study Locations (1)

California

  • Huntington Memorial Hospital - Pasadena

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-05
Est. Completion 2011-07
Phase Phase 2

Sponsor

Ferring Pharmaceuticals

83 total trials

What the Registry Record Tells You About NCT01283022

The ClinicalTrials.gov registry entry for NCT01283022 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 468-participant average among 8 other Cervical Ripening trials with a reported enrollment target (95% lower). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cervical Ripening appearing as the primary indexed condition, and to 1 intervention - of which MVI 200 is the first listed.

NCT01283022 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01283022 about?

NCT01283022 is a clinical study titled "Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)". The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.

What is the current status of trial NCT01283022?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-05. Estimated completion is 2011-07.

What conditions does trial NCT01283022 study?

This clinical trial studies the following conditions: Cervical Ripening, Induction of Labor.

What interventions are being tested in trial NCT01283022?

The interventions under investigation include: MVI 200 (DRUG).

Who is sponsoring clinical trial NCT01283022?

This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01283022 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervical Ripening

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.